Skip to contentX
Xenetic Biosciences, Inc.
X
XBIOXenetic Biosciences, Inc. Q1 2025 · 10-Q
Revenue$593.26K$593.26K+16.1% vs Q1 2024 Net Income-$903.14K-$903.14KN/M vs Q1 2024 EPS Diluted-$0.59-$0.59N/M vs Q1 2024 Operating Income-$942,409N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenetic Biosciences, Inc. · CIK 1534525 · Engraved from SEC EDGAR
Margins · derivedOperating margin-158.9%+89.5 pt vs Q1 2024
Net margin-152.2%+81.7 pt vs Q1 2024
ended Mar 31, 2025 · filed May 13, 2025 · 43 d after period end